These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26077729)

  • 1. Current Drug Targets for Thymic Neoplasms.
    Xu XL; Mao WM
    Curr Cancer Drug Targets; 2015; 15(7):593-603. PubMed ID: 26077729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precise Diagnosis and Treatment of Thymic Epithelial Tumors Based on Molecular Biomarkers.
    Du J; Zhou XJ
    Crit Rev Oncog; 2017; 22(5-6):507-514. PubMed ID: 29604928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Agents in the Treatment of Thymic Malignancies.
    Merveilleux du Vignaux C; Maury JM; Girard N
    Curr Treat Options Oncol; 2017 Aug; 18(9):52. PubMed ID: 28795288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do thymic malignancies respond to target therapies?
    Hu B; Rong H; Han Y; Li Q
    Interact Cardiovasc Thorac Surg; 2015 Jun; 20(6):855-9. PubMed ID: 25754373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors.
    Serpico D; Trama A; Haspinger ER; Agustoni F; Botta L; Berardi R; Palmieri G; Zucali P; Gallucci R; Broggini M; Gatta G; Pastorino U; Pelosi G; de Braud F; Garassino MC
    Ann Oncol; 2015 May; 26(5):838-847. PubMed ID: 25411417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy and targeted agents for thymic malignancies.
    Girard N
    Expert Rev Anticancer Ther; 2012 May; 12(5):685-95. PubMed ID: 22594902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymic epithelial tumours: from basic principles to individualised treatment strategies.
    Girard N
    Eur Respir Rev; 2013 Mar; 22(127):75-87. PubMed ID: 23457169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
    Thomas A; Rajan A; Berman A; Tomita Y; Brzezniak C; Lee MJ; Lee S; Ling A; Spittler AJ; Carter CA; Guha U; Wang Y; Szabo E; Meltzer P; Steinberg SM; Trepel JB; Loehrer PJ; Giaccone G
    Lancet Oncol; 2015 Feb; 16(2):177-86. PubMed ID: 25592632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy for advanced thymic tumors.
    Rajan A; Giaccone G
    J Thorac Oncol; 2010 Oct; 5(10 Suppl 4):S361-4. PubMed ID: 20859134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular aspects of thymic carcinoma.
    Weissferdt A; Wistuba II; Moran CA
    Lung Cancer; 2012 Nov; 78(2):127-32. PubMed ID: 22921473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports.
    Simonelli M; Zucali PA; Suter MB; Lorenzi E; Rubino L; Fatuzzo G; Alloisio M; Santoro A
    Future Oncol; 2015; 11(8):1223-32. PubMed ID: 25832879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review.
    Berardi R; De Lisa M; Pagliaretta S; Onofri A; Morgese F; Savini A; Ballatore Z; Caramanti M; Santoni M; Mazzanti P; Cascinu S
    Cancer Treat Rev; 2014 May; 40(4):495-506. PubMed ID: 24355362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemotherapy for thymic carcinoma].
    Okuma Y
    Gan To Kagaku Ryoho; 2012 May; 39(5):702-7. PubMed ID: 22584319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When a thymic carcinoma "becomes" a GIST.
    Rossi V; Donini M; Sergio P; Passalacqua R; Rossi G; Buti S
    Lung Cancer; 2013 Apr; 80(1):106-8. PubMed ID: 23375402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymic malignancies: Moving forward with new systemic treatments.
    Remon J; Lindsay CR; Bluthgen MV; Besse B
    Cancer Treat Rev; 2016 May; 46():27-34. PubMed ID: 27057658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report.
    Li XF; Chen Q; Huang WX; Ye YB
    Med Oncol; 2009; 26(2):157-60. PubMed ID: 18846437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of chemotherapy in advanced thymoma.
    Schmitt J; Loehrer PJ
    J Thorac Oncol; 2010 Oct; 5(10 Suppl 4):S357-60. PubMed ID: 20859133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma.
    Hirai F; Seto T; Yamanaka T; Toyozawa R; Inamasu E; Kojo M; Toyokawa G; Morodomi Y; Shiraishi Y; Takenaka T; Yamaguchi M; Takenoyama M; Ichinose Y
    Jpn J Clin Oncol; 2013 Oct; 43(10):1018-22. PubMed ID: 23917962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Research status of molecular targeted therapy in thymic epithelial tumors].
    Chen L; Wu K
    Zhongguo Fei Ai Za Zhi; 2014 Jun; 17(6):487-90. PubMed ID: 24949690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.
    Pagano M; Sierra NM; Panebianco M; Rossi G; Gnoni R; Bisagni G; Boni C
    Anticancer Res; 2014 Sep; 34(9):5105-10. PubMed ID: 25202099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.